Radiation therapy in the management of rectal cancer

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 300-306

  Kachnic, Lisa A ^a   Willett, Christopher G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ANUS SPHINCTER; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CONTROLLED STUDY; HUMAN; MORBIDITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; REVIEW;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; RECTAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034960279     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00014     Document Type: Review

References (61)

1. Conservative treatment of rectal cancer: Extending the indication
2. Update of the Massachusetts General Hospital experience of combined local excision and radiotherapy for rectal cancer
3. Current protocols and outcome of local therapy for rectal cancer
4. Variables correlated with the risk of lymph mode metastasis in early rectal cancer
5. Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal cancer
6. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation
7. Local excision and postoperative radiation therapy for rectal carcinoma
8. Long-term follow-up of local excision and radiation therapy for invasive rectal cancer
9. Conservative management of rectal cancer with local excision and postoperative adjuvant therapy
10. Sphincter-sparing treatment for distal rectal adenocarcinoma
11. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: Long-term results of radiation therapy oncology group protocol 89-02
12. Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology
13. Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer
14. Adjuvant radiation therapy for rectal carcinoma: Predictors of outcome
15. Preoperative infusional chemoirradiation for stage T3 rectal cancer
16. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum
17. Enhancement of radiation-induced downstaging of rectal cancer by 5-FU and high-dose leucovorin chemotherapy
18. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis
19. Sphincter prevention with preoperative radiation therapy and coloanal anastomosis
20. Conservative surgery for low rectal cancer after high dose radiation
21. High dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal rectum
22. Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial
23. Sphincter sparing surgery after preoperative radiotherapy for low rectal cancers: Feasibility, oncologic results and quality of life outcomes
24. Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathologic complete response
25. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter sparing surgery for rectal cancer: The Lyon R990-01 randomized trial
26. Adjuvant postoperative radiation therapy for rectal adenocarcinoma
27. Postoperative adjuvant radiotherapy for adenocarcinoma of the rectum and rectosigmoid
28. Prolongation of the disease-free survival in surgically treated rectal carcinoma
29. Effective surgical adjuvant therapy for high risk rectal carcinoma
30. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP Protocol R-01
31. Adjuvant therapy for patients with colon and rectal cancer
32. Radiation therapy and 5-FU with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum
33. Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5-FU with radiation therapy after curative surgery
34. Adjuvant postoperative fluorouracil modulated chemotherapy for rectal cancer: Initial results of Intergroup 0114
35. Randomized trial of postoperative adjuvant chemotherapy with or without radiation for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
36. Total mesorectal excision with autonomic nerve preservation: A new foundation for the evaluation of multi-disciplinary adjuvant therapy in the management of rectal cancers
37. Selective total mesorectal excision for rectal cancer
38. Prognostic factors in stage T3N0 rectal cancer: Do all patients require postoperative pelvic irradiation and chemotherapy
39. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R-03
40. Adjuvant and neoadjuvant radiochemotherapy for advanced rectal cancer: First results of the German multicenter phase-III-trial
41. The incidence and clinical consequences of treatment-related bowel injury
42. Treatment planning for colorectal cancer: Radiation and surgical techniques and value of small-bowel films
43. Pelvic radiation therapy in rectal cancer: Technical considerations
44. Influence of patient positioning on dose-volume histogram and normal tissue complication probability for small bowel and bladder in patients receiving pelvic irradiation: A prospective study using a 3D planning system and a radiobiological model
45. Technical advances in the treatment of patients with rectal cancer
46. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer
47. Tumor proliferation in rectal cancer following preoperative irradiation
48. Alteration of DNA ploidy status and cell proliferation induced by preoperative radiotherapy is a prognostic factor in rectal cancer
49. Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients
50. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer
51. Can p53 alterations be used to predict tumour response to preoperative chemotherapy in locally advanced rectal cancer?
52. Molecular prognostic factors in rectal cancer treated by radiation and surgery
53. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
54. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leukovorin
55. Open, randomized, multi-center trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
56. Oral fluoropyrimidines
57. UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer
58. Multicenter phase III trial of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectat cancer
59. Randomized comparative study of ORZEL (oral uracil/tegafur (UFT™) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer
60. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer
61. Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin